Prognostic factors of primary transitional cell carcinoma of the upper urinary tract

S. H. Lee, J. S.N. Lin, T. S. Tzai, Nan-Haw Chow, Yat-Ching Tong, Wen-Horng Yang, C. C. Chang, Hong-Lin Cheng

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Objectives: We presented and analyzed our results in order to determine the relationship between patient survival and tumor grade and/or stage. In addition, a retrospective tumor DNA ploidy study was done to evaluate its possible role in predicting future tumor recurrence in the bladder. Methods: A total of 112 patients with upper urinary tract transitional cell carcinomas (TCCs) were recorded at our hospital. Of these, 68 patients without concurrent bladder tumors (ages ranged from 36 to 80, mean 62.4 years; male:female = 1:1.2) were treated by nephroureterectomy and bladder cuff resection. They were followed up for 14-79 months (average 38.2 months). Eight (36.4%) of the 22 patients who had stage C or D tumors had received adjuvant systemic methotrexate, vinblastine, epirubicin, cisplatin chemotherapy after surgery. DNA flow cytometry using paraffin-blocked tumor specimens was performed on the tumors of 52 patients. Results: Their pathologic stages and grades were 11 at stage 0, 15 at stage A, 20 at stage B, 14 at stage C, 8 at stage D; 9 of grade I, 41 of grade II, and 18 of grade III. Postoperatively, 13 patients (19.1%) subsequently developed bladder tumors with a latent period ranging from 2 to 37 months (average 14.9 months). The difference of the tumor DNA ploidy distribution pattern among tumors of high versus low stages and/or grades is not statistically significant (p > 0.05). Overall, the 5-year survival rates for patients with low- and high-stage tumors were 100 and 66.7%, respectively; for patients with grade I-II and III tumors they were 93.6 and 28.3%, respectively. Conclusions: Patient survival was mainly related to both tumor stages (p = 0.0037) and grades (p = 0.0001), rather than to tumor DNA ploidy. For patients with grade II upper urinary tract tumors, tumor DNA ploidy seems to provide no additional predictive value on subsequent tumor recurrence in the bladder.

Original languageEnglish
Pages (from-to)266-271
Number of pages6
JournalEuropean Urology
Volume29
Issue number3
DOIs
Publication statusPublished - 1996 Jan 1

Fingerprint

Transitional Cell Carcinoma
Urinary Tract
Neoplasms
Ploidies
DNA
Urinary Bladder
Urinary Bladder Neoplasms
Recurrence
Epirubicin
Survival
Vinblastine
Methotrexate
Paraffin
Cisplatin

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

@article{be2c9cc7b980479bbdcc4e1cc78c5afd,
title = "Prognostic factors of primary transitional cell carcinoma of the upper urinary tract",
abstract = "Objectives: We presented and analyzed our results in order to determine the relationship between patient survival and tumor grade and/or stage. In addition, a retrospective tumor DNA ploidy study was done to evaluate its possible role in predicting future tumor recurrence in the bladder. Methods: A total of 112 patients with upper urinary tract transitional cell carcinomas (TCCs) were recorded at our hospital. Of these, 68 patients without concurrent bladder tumors (ages ranged from 36 to 80, mean 62.4 years; male:female = 1:1.2) were treated by nephroureterectomy and bladder cuff resection. They were followed up for 14-79 months (average 38.2 months). Eight (36.4{\%}) of the 22 patients who had stage C or D tumors had received adjuvant systemic methotrexate, vinblastine, epirubicin, cisplatin chemotherapy after surgery. DNA flow cytometry using paraffin-blocked tumor specimens was performed on the tumors of 52 patients. Results: Their pathologic stages and grades were 11 at stage 0, 15 at stage A, 20 at stage B, 14 at stage C, 8 at stage D; 9 of grade I, 41 of grade II, and 18 of grade III. Postoperatively, 13 patients (19.1{\%}) subsequently developed bladder tumors with a latent period ranging from 2 to 37 months (average 14.9 months). The difference of the tumor DNA ploidy distribution pattern among tumors of high versus low stages and/or grades is not statistically significant (p > 0.05). Overall, the 5-year survival rates for patients with low- and high-stage tumors were 100 and 66.7{\%}, respectively; for patients with grade I-II and III tumors they were 93.6 and 28.3{\%}, respectively. Conclusions: Patient survival was mainly related to both tumor stages (p = 0.0037) and grades (p = 0.0001), rather than to tumor DNA ploidy. For patients with grade II upper urinary tract tumors, tumor DNA ploidy seems to provide no additional predictive value on subsequent tumor recurrence in the bladder.",
author = "Lee, {S. H.} and Lin, {J. S.N.} and Tzai, {T. S.} and Nan-Haw Chow and Yat-Ching Tong and Wen-Horng Yang and Chang, {C. C.} and Hong-Lin Cheng",
year = "1996",
month = "1",
day = "1",
doi = "10.1159/000473758",
language = "English",
volume = "29",
pages = "266--271",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "3",

}

Prognostic factors of primary transitional cell carcinoma of the upper urinary tract. / Lee, S. H.; Lin, J. S.N.; Tzai, T. S.; Chow, Nan-Haw; Tong, Yat-Ching; Yang, Wen-Horng; Chang, C. C.; Cheng, Hong-Lin.

In: European Urology, Vol. 29, No. 3, 01.01.1996, p. 266-271.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic factors of primary transitional cell carcinoma of the upper urinary tract

AU - Lee, S. H.

AU - Lin, J. S.N.

AU - Tzai, T. S.

AU - Chow, Nan-Haw

AU - Tong, Yat-Ching

AU - Yang, Wen-Horng

AU - Chang, C. C.

AU - Cheng, Hong-Lin

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Objectives: We presented and analyzed our results in order to determine the relationship between patient survival and tumor grade and/or stage. In addition, a retrospective tumor DNA ploidy study was done to evaluate its possible role in predicting future tumor recurrence in the bladder. Methods: A total of 112 patients with upper urinary tract transitional cell carcinomas (TCCs) were recorded at our hospital. Of these, 68 patients without concurrent bladder tumors (ages ranged from 36 to 80, mean 62.4 years; male:female = 1:1.2) were treated by nephroureterectomy and bladder cuff resection. They were followed up for 14-79 months (average 38.2 months). Eight (36.4%) of the 22 patients who had stage C or D tumors had received adjuvant systemic methotrexate, vinblastine, epirubicin, cisplatin chemotherapy after surgery. DNA flow cytometry using paraffin-blocked tumor specimens was performed on the tumors of 52 patients. Results: Their pathologic stages and grades were 11 at stage 0, 15 at stage A, 20 at stage B, 14 at stage C, 8 at stage D; 9 of grade I, 41 of grade II, and 18 of grade III. Postoperatively, 13 patients (19.1%) subsequently developed bladder tumors with a latent period ranging from 2 to 37 months (average 14.9 months). The difference of the tumor DNA ploidy distribution pattern among tumors of high versus low stages and/or grades is not statistically significant (p > 0.05). Overall, the 5-year survival rates for patients with low- and high-stage tumors were 100 and 66.7%, respectively; for patients with grade I-II and III tumors they were 93.6 and 28.3%, respectively. Conclusions: Patient survival was mainly related to both tumor stages (p = 0.0037) and grades (p = 0.0001), rather than to tumor DNA ploidy. For patients with grade II upper urinary tract tumors, tumor DNA ploidy seems to provide no additional predictive value on subsequent tumor recurrence in the bladder.

AB - Objectives: We presented and analyzed our results in order to determine the relationship between patient survival and tumor grade and/or stage. In addition, a retrospective tumor DNA ploidy study was done to evaluate its possible role in predicting future tumor recurrence in the bladder. Methods: A total of 112 patients with upper urinary tract transitional cell carcinomas (TCCs) were recorded at our hospital. Of these, 68 patients without concurrent bladder tumors (ages ranged from 36 to 80, mean 62.4 years; male:female = 1:1.2) were treated by nephroureterectomy and bladder cuff resection. They were followed up for 14-79 months (average 38.2 months). Eight (36.4%) of the 22 patients who had stage C or D tumors had received adjuvant systemic methotrexate, vinblastine, epirubicin, cisplatin chemotherapy after surgery. DNA flow cytometry using paraffin-blocked tumor specimens was performed on the tumors of 52 patients. Results: Their pathologic stages and grades were 11 at stage 0, 15 at stage A, 20 at stage B, 14 at stage C, 8 at stage D; 9 of grade I, 41 of grade II, and 18 of grade III. Postoperatively, 13 patients (19.1%) subsequently developed bladder tumors with a latent period ranging from 2 to 37 months (average 14.9 months). The difference of the tumor DNA ploidy distribution pattern among tumors of high versus low stages and/or grades is not statistically significant (p > 0.05). Overall, the 5-year survival rates for patients with low- and high-stage tumors were 100 and 66.7%, respectively; for patients with grade I-II and III tumors they were 93.6 and 28.3%, respectively. Conclusions: Patient survival was mainly related to both tumor stages (p = 0.0037) and grades (p = 0.0001), rather than to tumor DNA ploidy. For patients with grade II upper urinary tract tumors, tumor DNA ploidy seems to provide no additional predictive value on subsequent tumor recurrence in the bladder.

UR - http://www.scopus.com/inward/record.url?scp=0029975830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029975830&partnerID=8YFLogxK

U2 - 10.1159/000473758

DO - 10.1159/000473758

M3 - Article

VL - 29

SP - 266

EP - 271

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 3

ER -